Related Experiment Video
Updated: Oct 12, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases
1Centre Hospitalier Universitaire, Angers, France.
Abstract:
Microalbuminuria, a slightly elevated urinary albumin excretion, predicts renal failure in insulin-dependent diabetic patients and premature cardiovascular mortality in non-insulin-dependent diabetic patients and in the general population. It can be related to all currently established cardiovascular risk factors. Regarding the relationship between urinary albumin and blood pressure, microalbuminuria seems to be an early indicator of renal disease, causing high blood pressure in some instances, whereas it looks like the consequences of renal damage produced by severe hypertension in other instances. To establish whether microalbuminuria is an integrated risk marker for renal and cardiovascular events, or truly a risk factor, and to validate the usefulness of some peculiar treatment strategies, clinical trials are required, taking microalbuminuria as a selection criteria, and renal and cardiovascular events as endpoints.
Insights
Microalbuminuria, an early sign of kidney disease, predicts kidney failure and cardiovascular risks in diabetic and general populations. Further clinical trials are needed to confirm its role as a risk factor and evaluate treatments.
Area of Science:
- Nephrology
- Cardiology
- Diabetology
Background:
- Microalbuminuria, characterized by slightly elevated urinary albumin, is a predictor of renal failure in type 1 diabetes and cardiovascular mortality in type 2 diabetes and the general population.
- It is associated with established cardiovascular risk factors and has a complex relationship with blood pressure, potentially indicating early renal disease or resulting from severe hypertension.
Purpose of the Study:
- To determine if microalbuminuria is an integrated risk marker or a true risk factor for renal and cardiovascular events.
- To validate the efficacy of specific treatment strategies for microalbuminuria.
Main Methods:
- The abstract suggests the need for clinical trials.
- These trials should use microalbuminuria as a selection criterion.
- Renal and cardiovascular events should be the primary endpoints.
Main Results:
- The abstract does not contain specific results as it calls for further clinical trials.
Conclusions:
- Clinical trials are required to definitively establish microalbuminuria's role as a risk marker or factor.
- These trials are essential for validating treatment strategies targeting microalbuminuria.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
